Fei Wang1, Wei Xu2, Wei-Ying Gu1, Jian-Yong Li3. 1. Department of Hematology, The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou 213003, Jiangsu Province, China. 2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial people Hospital), Nanjing 210029, Jiangsu Province, China. 3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial people Hospital), Nanjing 210029, Jiangsu Province, China,E-mail: lijianyonglm@126.com.
Abstract
OBJECTIVE: To explore the expression of miR-155 in patients with chronic lymphocytic leukemia (CLL) and its correlation with the clinical and biological features in CLL. METHODS: The expression of miR-155 was detected by quantitative real time polymerase chain reaction (qRT-PCR) in the peripheral mononuclear cells collected from 73 CLL patients and CD19 positive B cells collected from 60 healthy controls, respectively. The expression of miR-155 in CLL patients was compared with the healthy controls, and the correlation of miR-155 expression with the clinical characteristics of CLL patients such as age, sex, Binet stage, cytogenetic and molecular genetic, as well as the relationship of miR-155 expression level with time to treatment (TTT) and overall survival (OS) was further analysed. RESULTS: The expression of miR-155 was significantly elevated in CLL patients compared with the healthy controls. Further analysis showed that miR-155 expression decreased in the patients with the mutated immunoglobulin heavy chian variable region (IGHV) as compared with the patients unmutated (P＜0.05), and its expression was significant higher in the IGHV-39 family (P＜0.05). Fluorescence in situ hybridization (FISH) showed that the expression of miR-155 increased in patients with P53 mmutation/deletion and ATM deletion (P＜0.05). However, OS and TTT were not different between the patients with high and low expression of miR-155. CONCLUSION: MiR-155 is increasingly expresses in CLL patients and correlates with poor prognosis, suggesting its important role in the genesis and progress of CLL.
OBJECTIVE: To explore the expression of miR-155 in patients with chronic lymphocytic leukemia (CLL) and its correlation with the clinical and biological features in CLL. METHODS: The expression of miR-155 was detected by quantitative real time polymerase chain reaction (qRT-PCR) in the peripheral mononuclear cells collected from 73 CLLpatients and CD19 positive B cells collected from 60 healthy controls, respectively. The expression of miR-155 in CLLpatients was compared with the healthy controls, and the correlation of miR-155 expression with the clinical characteristics of CLLpatients such as age, sex, Binet stage, cytogenetic and molecular genetic, as well as the relationship of miR-155 expression level with time to treatment (TTT) and overall survival (OS) was further analysed. RESULTS: The expression of miR-155 was significantly elevated in CLLpatients compared with the healthy controls. Further analysis showed that miR-155 expression decreased in the patients with the mutated immunoglobulin heavy chian variable region (IGHV) as compared with the patients unmutated (P＜0.05), and its expression was significant higher in the IGHV-39 family (P＜0.05). Fluorescence in situ hybridization (FISH) showed that the expression of miR-155 increased in patients with P53 mmutation/deletion and ATM deletion (P＜0.05). However, OS and TTT were not different between the patients with high and low expression of miR-155. CONCLUSION:MiR-155 is increasingly expresses in CLLpatients and correlates with poor prognosis, suggesting its important role in the genesis and progress of CLL.